Navigation Links
FluoroPharma Announces Commencement of Phase I Clinical Trial for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
Date:3/19/2008

BOSTON, March 19 /PRNewswire/ -- FluoroPharma Inc., a company developing breakthrough cardiovascular molecular imaging agents for the Positron Emission Tomography (PET) market, announced commencement of Phase I clinical trials for BFPET, following institutional review board (IRB) approval of the proposed studies. The Phase I trial is a single center, open label study, designed to evaluate safety, distribution and dosimetry of BFPET as a PET tracer for myocardial perfusion imaging in healthy subjects. The study will be led by Dr. Alan Fischman, Professor of Radiology at Harvard Medical School and former Director of the Nuclear Medicine Division at Massachusetts General Hospital. BFPET is FluoroPharma's second cardiovascular PET agent to enter clinical trials.

BFPET is a PET blood flow imaging agent, for use in classic "rest-stress" cardiac testing. More than 9 million Americans each year undergo myocardial perfusion imaging, the standard test to assess coronary artery disease (CAD). BFPET, as a PET imaging tracer, may have a significant advantage due to its potential to improve the sensitivity and specificity of CAD diagnosis and to provide information on myocardial mitochondrial damage. "This agent, if successful, should improve CAD diagnosis and follow-up of therapy and intervention, and broaden the utility of PET as an imaging modality," said Dr. David Elmaleh, FluoroPharma's Chairman and Scientific Founder. "BFPET has performed well in animals with a target-to-blood ratio of 70:1, and we look forward to evaluating the agent in human studies."

"We are delighted to have our second product enter clinical trials," said Dr. Ljiljana Kundakovic, FluoroPharma's President. "BFPET's progress follows on the tail of CardioPET, an agent for the detection of metabolic integrity of the heart, which recently completed a Phase I safety evaluation in normal healthy volunteers and cardiac patients. FluoroPharma has the potential to significantly impact diagnos
'/>"/>

SOURCE FluoroPharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. FluoroPharma Announces Positive Phase I Safety Results for CardioPET(TM), Coronary Artery Disease (CAD) Imaging Tracer for Positron Emission Tomography (PET)
2. Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen(R) Technology at Lower Doses
3. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
4. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
5. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
6. Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
7. MacroChem Announces Presentation of Pexiganan Phase 3 Study Results for Topical Treatment of Diabetic Foot Infection
8. Synbiotics Corporation Announces Human Submission for FluDetect(R)
9. Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic Cancer
10. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
11. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... -- Sony Biotechnology Inc. ("Sony") today announced the launch of ... be exhibiting and taking orders for this system at ... San Diego Convention Center in ... - 22.  The SP6800 Spectral Analyzer ... into new and novel functionalities for the immunology, oncology, ...
(Date:5/17/2013)... that it will report its 2013 first quarter earnings on Wednesday, May ... Ed Borkowski , CFO, will host an analyst and investor call ... in the conference call within the U.S. and Canada ... outside the U.S. and Canada , dial (760) 666-3086. ... dial in 10 minutes prior to the start of the call. The ...
(Date:5/17/2013)...  Boehringer Ingelheim will contribute to advancing the ... Thoracic Society International Conference (ATS 2013) in ... 22. Data will highlight research conducted ... chronic obstructive pulmonary disease (COPD) [Spiriva® HandiHaler® (tiotropium ... for asthma, idiopathic pulmonary fibrosis (IPF) and COPD. ...
Breaking Medicine Technology:Sony Biotechnology Inc.'s New Technology for Science Provides Researchers Results in Color 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8
... 1, 2012 Heart IT, the global leader ... medical imaging workstation, WebPAX®, announced today the award ... viewing technologies. "Zero-footprint" technologies allow health care professionals ... with a standard Internet web browser. ...
... (NASDAQ: ANGN ) today announced it has ... Global Sales effective May 7, 2012. Mr. Margolies will ... worldwide sales organization and delivering sales results to achieve ... Mr. Margolies will be succeeding James Gaul, senior vice ...
Cached Medicine Technology:U.S. Patent Office Issues Sixth Patent Covering 'Zero-Footprint' Medical Image Viewers to Heart Imaging Technologies, LLC 2Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales 2Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales 3Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales 4
(Date:5/19/2013)... 19, 2013 Today, Zane Benefits, ... business health insurance . Zane Benefits, which provides ... health benefits, is the leader in health care ... reimbursement arrangements . , According to Zane Benefits’ ... intrinsically know the value of small business health ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 The report ... Global Trends & Forecasts up to 2017” published by ... market with analysis and forecasting of the global volume ... identifies the driving and restraining factors for the global ... imperatives, and challenges. The market is segmented and revenue ...
(Date:5/19/2013)... Chertok now provides gum disease patients with a new alternative ... of a healthier smile. Laser gum surgery or ... diseased gum tissue in patients, but it also stimulates bone ... , LANAP uses a laser to successfully treat and ... healthy tissue as well as encourage new bone growth. With ...
(Date:5/19/2013)... St. Petersburg, FL (PRWEB) May 19, 2013 ... Sublime Beauty ®, who is reintroducing a great practice ... today. "Skin Brushing, also known as dry body brushing, ... says Kathy Heshelow, founder of Sublime Beauty®. "We love ... that functioning of our largest organ, the skin, is ...
(Date:5/19/2013)... Ponte Vedra Beach, Florida (PRWEB) May 19, 2013 ... healthcare value and market access, is pleased to unveil ... online trade show environment that provides a powerful array ... solutions to partners in the US and abroad. , ... technology, and will offer attendees the look and feel ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 2Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 3Health News:Feed Additives Market to Reach $19.5 Billion by 2017 at a CAGR of 3.8% - New Report by MarketandMarkets 2Health News:Feed Additives Market to Reach $19.5 Billion by 2017 at a CAGR of 3.8% - New Report by MarketandMarkets 3Health News:Berkeley, CA Periodontist, Dr. Keith Chertok Now Treats Gum Disease Patients With Laser Gum Surgery Prior to Placing Dental Implants 2Health News:Exciting New Skin Brushes at Sublime Beauty® Bring Health and Beauty Benefits; Celebrities and Models Know the Secret 2Health News:HealthEconomics.Com Announces HE-Xpo, a New Virtual Trade Show Devoted to Healthcare Value and Market Access 2Health News:HealthEconomics.Com Announces HE-Xpo, a New Virtual Trade Show Devoted to Healthcare Value and Market Access 3
... available at the local tavern might be doing more ... role in suppressing social anxiety. New research from the ... sodium blunt the body,s natural responses to stress by ... stressful situations. These hormones are located along the hypothalamic-pituitary-adrenal ...
... An editorial in the April 6 issue of the ... hormone therapy in women who have had a hysterectomy because ... cancer. The editorial is a response to a study ... estrogen-only therapy, currently used in women with menopausal symptoms who ...
... Elderly U.S. veterans are far less likely to die after hospitalization ... new study indicates. Researchers examined data on more than 21,000 ... for heart failure between 1999 and 2008. They found ... 14 percent to 7 percent during that time, and death rates ...
... 2011 A UT Southwestern Medical Center gynecologist is ... $600,000 Burroughs Wellcome Fund grant to investigate the biological ... S. Mahendroo, associate professor of obstetrics and gynecology in ... Biological Sciences, will use the support to develop a ...
... , TUESDAY, April 5 (HealthDay News) -- The substantial ... U.S. hospital emergency departments between 1995 and 2008 highlights ... exams, say researchers. They analyzed National Hospital Ambulatory ... of children rose from about 330,000 in 1995 to ...
... Each year, more than 100,000 patients in the U.S. ... for heart rhythm abnormalities. This number constitutes a 20-fold ... advocate discussion of end of life care of these ... understand their options. Now, researchers at the University of ...
Cached Medicine News:Health News:Elevated levels of sodium blunt response to stress, study shows 2Health News:Caution for estrogen therapy after hysterectomy 2Health News:Caution for estrogen therapy after hysterectomy 3Health News:U.S. Vets' Heart Failure Death Rates Seem to Be Improving 2Health News:Grant helps UT Southwestern researcher study causes of preterm birth 2Health News:As CT Scans of Kids Soar, Experts Urge Oversight 2Health News:Penn study sheds light on end of life management of implanted defibrillators 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: